Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety - Wikidata - awgldk - TriplyDB

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

http://www.wikidata.org/entity/Q35825582

about

Voriconazole therapeutic drug monitoring.Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.Voriconazole pharmacokinetics in liver transplant recipients.Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy Cyclodextrin-based pharmaceutics: past, present and future.Inflammation is associated with voriconazole trough concentrations.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects In vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis.Pharmacokinetics of antifungal agents in children.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole Invasive fungal infections in acute leukemia.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy.Antifungal therapeutic drug monitoring: established and emerging indications.New and investigational triazole agents for the treatment of invasive fungal infections.Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole Pharmacogenomics of the triazole antifungal agent voriconazole.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients.Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.

P2860

Q24542411-E21A5F65-1503-464A-B688-054ED112971B Q33257899-A89EBAEF-6F58-4573-BD36-F8253828197C Q33392206-43ECE6B4-216E-4218-99DB-15354B53B31A Q33613685-745CA184-0FCC-42E3-B37D-801F3503D0AB Q34045383-8B38831B-2867-41D1-8BBA-9D2C3A472CD0 Q34138276-ECA626B4-A91B-40A5-A1BC-26B68F4AD537 Q34290034-3C68E4FF-A35D-4680-81DD-12C1EBAF56AC Q34413393-48637E20-BC85-4EB5-8C8A-726889A6B914 Q34552997-7727A78D-5004-4FB1-8F17-BA9B3233B16B Q34597394-EEF5DE23-8B89-40E4-AB80-002C764CCC7B Q35270270-E8B0A6CC-B5D8-41EB-9CF0-06358632261D Q35364006-5583F3B1-3225-43D7-8A6F-9F6D9B74C40E Q35635928-6DC660BD-CE50-4D7F-84BF-EAE5C2C2792D Q35647746-5E3AFA72-073A-43A4-A46E-FC465B8C5192 Q35959476-0D33E5C3-035F-4096-9F7D-88B88B2595DD Q35973357-3CF5BAF3-706A-409D-AD71-4A08B579018F Q36024937-5241250E-67B0-4B16-AC01-941DD6283A0C Q36094896-C9C0FBFB-8B9F-4976-9EBF-C52E13BCD2DE Q36163345-74C28C76-5580-457F-AB6C-F1882C598E0B Q36521993-513C7930-6A40-4C12-B5B7-E8461D3A6A64 Q36612597-66BB0157-194A-4D65-9404-184CC843A4A2 Q36887922-77904F35-6F49-4948-A9DD-6954038BAF7D Q36927577-411B3C86-5B08-41B5-A01D-AD83F219C2D6 Q37043539-63C1B03A-4494-4BF7-A530-7878D164E49C Q37263320-EC3541D2-91D8-4318-9E3D-C84E43877BCA Q37310029-066D9024-7D04-4B6B-A41A-382D7F3D8057 Q37364295-DE795EE6-B3B5-4C5B-BDFB-9369E98CFAB5 Q37471073-A9DBFD7A-7A2E-43DF-95F7-F304D21547B4 Q37892536-C90EB374-014D-42DE-8C08-CBCB5C216153 Q38193337-C1462BB6-0337-4477-8CAC-8569FE71DE82 Q38284468-3F9356BA-1C0B-4576-BCC0-46BA73360DE8 Q39932430-5E54DAC8-F81F-40CE-BF09-0733F3ADE98F Q40189236-662ADBA1-2E9B-4FAA-B80E-BD6888031608 Q41962141-37959E63-51CE-41FA-892F-2CF390AE1B1C Q42180308-C72856A7-A4EE-4237-AC25-5D10072A8062 Q42269872-51C42372-A413-4A9A-ADDF-BC3A06E7E16B Q42408726-F9F9DACB-3013-42B8-AAF6-960659CEB66E Q42623673-3530E38D-E03A-49DD-8A57-55CD1FC23A94 Q42666741-FD3D4B7A-3C4E-489F-B6FC-0C4252C9AEC5 Q44334907-E0F04AA5-FE2C-4F86-AD06-C118B8A75497

P2860

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

http://www.wikidata.org/entity/Q35825582

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

@ast

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

@en

type

label

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

@ast

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

@en

prefLabel

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

@ast

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

@en

P1433

Q35825582-DFFD6753-7AD3-4B5A-86B5-505FA214074F

P1476

Q35825582-04CEA9B8-96F9-4093-90DC-7E8342F2D697

P2093

Q35825582-088D071D-1267-4023-8A96-F1EA0AAC51C7

Q35825582-21078FDB-1A08-4F73-9BE4-310B4C9E09A7

Q35825582-4627EC49-6FFA-4023-B994-0F7FA6B23476

Q35825582-9DE22F4A-D875-4AA3-9EE7-5E024873A779

Q35825582-FBA4955F-DCFB-40BB-BA82-1AE41CFE828E

P2860

Q35825582-047633B7-69D6-48D7-915F-0D40DCF0030B

Q35825582-0B02FC84-9D98-4105-9784-789786FA9E8F

Q35825582-0D865621-BF96-4BD8-AFB8-429856165533

Q35825582-16171A92-B5F4-470F-B3C8-6CBDFDEE0138

Q35825582-2FF8454F-9F88-4EC8-B33C-DC47A06D93FE

Q35825582-30EC25DB-D79E-4780-B628-9086D2DBD98E

Q35825582-358BE4E0-3918-4E08-9BAC-31EF66E2BFCB

Q35825582-35F87EE7-413F-48E1-ADB6-DD62A186066D

Q35825582-427981B0-1E35-4918-B2AB-6E782855404B

Q35825582-4D188CC8-57E9-4276-8650-36B8E1D9BF29

P304

Q35825582-628B96EE-798E-4996-BB23-1F17ECCC3BF8

P31

Q35825582-74148FF7-AB4C-4EF4-8C60-59C4C143AB55

P356

Q35825582-F85FCAE1-43FF-40BD-A37F-D28B6B6FCE3A

P407

Q35825582-E050E88D-8291-41C8-80AC-FC976F2CC43C

P478

Q35825582-918139E0-51FB-4F53-A695-0184985F8B3C

P577

Q35825582-69836849-AAE5-460A-BD9E-8498BA119CC1

P5875

Q35825582-303792A9-C52A-4428-9622-D6AED6494742

P698

Q35825582-0E830875-8610-4724-87CF-515D9CD75E3F

P932

Q35825582-340B55BE-CF55-4EDA-BD46-2FE023C269CD

P356

J.1365-2125.2003.01993.X

P1433

British Journal of Clinical Pharmacology

P1476

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety

@en

P2093

Katie Greenhalgh

http://www.w3.org/2001/XMLSchema#string

Lynn Purkins

http://www.w3.org/2001/XMLSchema#string

Michael J Allen

http://www.w3.org/2001/XMLSchema#string

Nolan Wood

http://www.w3.org/2001/XMLSchema#string

Stuart D Oliver

http://www.w3.org/2001/XMLSchema#string

P2860

Current and emerging azole antifungal agents

In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Current management of fungal infections.

Uncommon opportunistic fungi: new nosocomial threats.

Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.

Emerging pathogens.

Intravenous itraconazole.

Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?

Fungal infections: a growing threat

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

P304

10-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2125.2003.01993.X

http://www.w3.org/2001/XMLSchema#string

P407

P478

56 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9010791

http://www.w3.org/2001/XMLSchema#string

P698

14616408

http://www.w3.org/2001/XMLSchema#string

P932

1884314

http://www.w3.org/2001/XMLSchema#string